top of page
Writer's pictureWireNews

The Dark Side of Ketamine: Questioning Its Efficacy in Depression Treatment

by Ram ben Ze'ev


The search for effective treatments for depression has led to various innovations in the field of mental health. One such controversial approach gaining popularity is the use of ketamine, a dissociative anesthetic, as a treatment for depression. While initial studies have suggested its potential, a closer examination reveals significant concerns and limitations. In this article, I will explore the reasons why using ketamine as a treatment for depression is an ill-advised and potentially harmful approach.


Ketamine has shown promise in rapidly alleviating depressive symptoms, often within hours or days after administration. However, this quick relief may come at a cost. The transient nature of its effects raises concerns about the sustainability of treatment. Ketamine's impact on depression tends to diminish over time, necessitating repeated doses to maintain its benefits. This poses a significant risk of dependence and addiction, which can exacerbate the already delicate mental health condition.


Despite its use as a depression treatment, the underlying mechanisms of how ketamine works in the brain are not yet fully understood. While ketamine's influence on the glutamate system is known, the long-term implications and potential side effects remain uncertain. Relying on a drug with limited scientific understanding can lead to unintended consequences and complications, making it an unreliable and potentially dangerous treatment option.


While initial studies have suggested the potential benefits of ketamine, the evidence supporting its long-term efficacy is still lacking. Most studies conducted to date have been short-term and involved small sample sizes, making it difficult to draw definitive conclusions about its long-term impact on depression. Without robust, well-controlled studies assessing its effectiveness over an extended period, it would be premature to embrace ketamine as a reliable treatment option.


Like any medication, ketamine carries a range of side effects and risks. These can include nausea, vomiting, dizziness, increased blood pressure, and dissociative experiences. Furthermore, long-term effects and potential risks, such as cognitive impairments and bladder toxicity, remain poorly understood. The use of ketamine as a depression treatment must be approached with caution due to the unknown consequences it may have on individuals' physical and mental well-being.


---> Follow on Twitter/X @rambenzeev and read all of RAM's articles on X


Ketamine treatment for depression often involves the use of expensive intravenous (IV) infusions or nasal sprays, making it inaccessible to many individuals due to financial constraints. This creates an ethical dilemma as the treatment becomes reserved for those who can afford it, potentially exacerbating disparities in mental health care. Moreover, prioritizing ketamine over evidence-based therapies may divert resources and attention from more established and effective treatments.


Depression is a complex condition that often requires a multifaceted approach for successful management. Relying solely on ketamine treatment neglects the importance of integrated care, including psychotherapy, social support, and lifestyle changes. Ketamine should be viewed as an adjunct treatment at best, rather than a standalone solution, in order to address the root causes of depression comprehensively.


While the initial excitement surrounding ketamine as a treatment for depression is understandable, it is crucial to approach this therapy with skepticism and caution. The lack of long-term evidence, the potential for addiction and dependence, unknown mechanisms, and associated risks and side effects all cast doubt on its reliability and suitability for widespread use. Instead of embracing ketamine as a quick fix, we must invest in evidence-based, comprehensive approaches to depression treatment that prioritize long-term well-being and sustainability.


###


Bill White (Ram ben Ze'ev) is CEO of WireNews and Executive Director of Hebrew Synagogue

bottom of page